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Introduction: Despite having a proven immunosuppressive potential in vitro, human mesenchymal stromal cells
(MSCs) are reported to display variable efficacy in vivo and, in fact, their proven benefit in the clinical practice is still
limited and controversial.
Methods: The interplay between clinical grade MSCs and pre-activated donor lymphocytes or selected lymphocyte
subsets was studied in vitro. The kinetics of MSC growth and viability was evaluated by adhesion-dependent
changes of culture plate impedance and biochemically by a colorimetric assay. Activation of natural killer (NK) cells
was assessed as well, using a flow cytometry assay.
Results: A strong inhibition of MSC growth was rapidly induced by the addition of pre-activated lymphocytes
but not of resting lymphocytes. Inhibition seems not to be attributable to a single cell population, as similar
results can be obtained by depleting NK cells or by using either selected CD4+ or CD8+ lymphocytes. In addition,
conditioned medium (CM) from activated lymphocytes was able to inhibit MSC growth in a dose-dependent
manner. Furthermore, licensing with IFN-γ partially protected MSCs from pre-activated lymphocytes but not from
their CM. These results suggest an inhibitory role of lymphocyte-activation-derived substances. However, the
identification of a single molecule responsible for MSC inhibition remained elusive, even if preliminary experiments
showed that ATP and, to a lesser extent, TNF-α might play a role.
Conclusions: These results suggest that survival of MSCs can be affected by soluble mediators released by
activated lymphocytes. Thus it can be hypothesized that MSC immunosuppressive action in vivo could be impaired
by ongoing immune activation through the release of inflammatory mediators.Introduction
Mesenchymal stromal cells (MSCs) are a heterogeneous
population of cells that can be obtained from bone mar-
row and from other adult tissues and are able to pro-
liferate in vitro as plastic-adherent fibroblast-like cells
[1-7]. In vitro, they have a potent immunosuppressive
action that justified their use in clinical trials for the
treatment of steroid-resistant graft versus host disease
(GvHD) and for severe autoimmune diseases. In fact,
MSCs are thought to be poorly immunogenic and have
been shown to have a highly safe profile in vivo. However,
the results of clinical trials so far showed heterogeneous* Correspondence: alberto.tommasini@burlo.trieste.it
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reproduction in any medium, provided the orefficacy [8-11], and contradictory results have been pub-
lished about their immunogenicity [12-14]. In particular, it
is becoming evident that microenvironmental factors may
play a major role in conditioning the immunosuppressive
action of MSCs. On one hand, natural killer (NK) cells are
able to kill MSCs in appropriate conditions [15]. On the
other hand, the immunosuppressive potency of MSCs
could be increased in vitro by their exposure to exogenous
molecules, such as lymphocyte-derived cytokines, such as
interferon-gamma (IFN-γ). For example, MSCs that have
been previously exposed in vitro to IFN-γ are resistant to
NK-cell-mediated lysis, maybe due to an up-regulation of
class 1 human leukocyte antigen (HLA-I) on their surface
[15,16]. As a matter of fact, pre-clinical results may vary
substantially according to the setting of the co-culture be-
tween lymphocytes and MSCs. We have previously shown
that whether lymphocytes are activated before or duringl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ther MSCs are treated or not with licensing-substances
before the co-culture are both critical factors influencing
the outcome of immunosuppression.
In our model, the stimulation of lymphocytes before
incubation with MSCs is meant to mimic the GvHD
condition in vivo, considering that the therapeutic use of
MSCs is proposed for patients with already active im-
mune responses. In this model, pre-activated lympho-
cytes are resistant to the action of MSCs, unless MSCs
have been previously exposed to IFN-γ [17].
In the present study, to unravel better the interactions
between lymphocytes and MSCs, we used a non-invasive
tool for real-time monitoring of the vitality and growth
of MSCs after the addition of peripheral blood mono-
nuclear cells (PBMCs) [18].
Methods
Cell culture
Human bone marrow MSCs were obtained at the La-
boratory for Cell and Gene Therapy ‘S Verri’, Monza,
Italy [11]. Side collections of clinical grade MSC prepa-
rations were dedicated to this research, after obtaining
the donors’ informed consent. The research plan was ap-
proved by the Institute Research Board (reference num-
ber #RC 32/11) and by the local ethics committee at the
IRCCS Burlo Garofolo, Trieste, Italy.
In brief, total nucleated cells were isolated from the
washouts of discarded bone marrow collection bags
and filters by washing both the filter and the empty
bag twice with phosphate-buffered saline and centrifu-
ging at 1,600 rpm for 5 minutes. The cells were plated at
500,000 cells/cm2 in Dulbecco’s modified essential me-
dium low glucose (Gibco-Invitrogen, Carlbad, CA, USA),
supplemented with 2 UI/ml heparin (Pharmatex, Milan,
Italy) and 5% platelet lysate (hPL) and cultured in 5% CO2
at 37°C. Non-adherent cells were removed after two to
three days and a 50% medium change was performed
twice weekly until 80% confluence. Cells were recovered
by trypsinization, re-plated at 200 cells/cm2 and cultured
for an additional 12 days. After trypsinization, the cells
were frozen in vials in 10% clinical grade dimethyl sulfox-
ide (DMSO) (WAK-Chemie Medica GmbH, Steinbach,
Germany) and 90% human AB plasma.
When ready to be used, the cells were thawed and
plated in T75 flask (Falcon, BD Biosciences, Bedford,
MA USA) at 8,000 cells/cm2 in Dulbecco’s modified
essential medium low glucose (Euroclone, Milan, Italy),
supplemented with 100 U/ml penicillin, 100 μg/ml strep-
tomycin, 200 mM L-glutamine (Euroclone), 5% platelet
lysate (called complete medium), and cultured in 5% CO2
at 37°C. Following trypsinization, at the third passage, the
cells were seeded in a 16-well electric microtiter plate for
the co-culture experiments.PBMCs were isolated from adult healthy volunteers,
after obtaining their informed consent according to the
local ethical committee, by centrifugation on biocoll
separating solution (Biochrom AG, Berlin, Germany)
at 560 × g for 30 minutes at room temperature. CD4+
and CD8+ cells were then separated by negative selec-
tion using magnetic sorting (Miltenyi Biotec, Bergisch
Gladbach, Germany). PBMCs depleted of CD56+ cells
were obtained using anti-CD56 coated beads (Miltenyi
Biotec).
PBMC, CD4+ cells, CD8+ cells, CD56-depleted PBMCs
were stimulated or not with 1 μg/ml phytohemagglutinin
(PHA) (Sigma Aldrich, Milan, Italy) 24 hours before the
co-culture and used as effector cells to test how they af-
fect MSC growth.
In a new set of experiments, MSCs were cultivated in
the presence of conditioned medium (CM) from 1 × 106
PBMCs activated with 1 μg/ml PHA or with anti CD3/
CD28 beads (Dynabeads® Human T-activator CD3/CD28,
Invitrogen Dynal AS, Oslo, Norway) in complete medium
for 24 hours.
CM from PBMCs, activated or not with PHA, were
assessed by means of a bead-based multiplex immuno-
assay (27 human-Bio-Plex assay; BioRad Laboratories,
Milan, Italy), following the manufacturer’s instructions.
Human cytokine and chemokine levels were measured
in duplicate, using the Bio-Plex 200 reader (Bio-Rad,
Hercules, CA, USA) equipped with Bioplex Manager 6
software.
Co-culture experiments with impedance measurements
Measurements were carried out with an xCELLigence
RTCA DP instrument (Roche, Penzberg, Germany). In
this instrument, the presence of adherent cells on the
bottom of the plate leads to an increase of electrode im-
pedance, which is converted in a ‘Cell Index’ (CI) that
depends on the number and viability of attached cells.
Thus, the death and detachment of cultured cells will be
recorded as a decrease in impedance. In this 16-well de-
vice (E-Plate 16) 400 MSCs/wells were plated in 200 μl
of complete medium and the impedance was measured
every five minutes.
Cells were allowed to attach and proliferate. When they
had reached their growth phase, as evidenced by curve
profiles, 100 μl of medium were removed and PBMCs
were added at varying cell ratios to seeded MSCs or CM
was added at varying dilutions.
In a set of experiments, attached MSCs were pre-treated
with IFN-γ (at a final concentration of 1,000 U/ml), 24
hours before the stimulation.
This impedance assay was reproduced four times with
different MSC populations, treated with PBMCs (or their
CM) from various healthy volunteers. Each experiment
used a single donor’s cells and was conducted in triplicate.
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The ability of MSCs to stimulate NK cells was investiga-
ted by flow cytometry, by measuring the MSC-induced
NK-degranulation as revealed by CD107a surface ex-
pression [19]. Briefly, 2 × 105 donor PBMCs (resting or
PHA-activated) and 2 × 105 MSCs were co-cultured in
suspension in the presence of anti-CD107a-PE (BD
Biosciences, San Jose, CA, USA). An equal number of
PBMCs was incubated with 2 × 105 K562 tumor cell
line (ATCC CCL 243), as positive control of degranula-
tion, or with medium alone (Iscove’s modified Dulbecco’s
medium, IMDM), as negative control. After two hours of
incubation at 37°C and 5% CO2 cells were harvested and
stained with CD3-PerCP and CD56 APC (both from BD
Biosciences). Data were acquired on a CyAn ADP flow
cytometer (Beckman Coulter, Fort Collins, CO, USA) and
analyzed using FlowJo software v 7.6 (TreeStar, Ashland,
OR, USA). The expression of CD107a was recorded on
CD3- CD56+ cell gate.
MTT cell viability assay
Cell viability was evaluated biochemically with the
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazo-
lium bromide) method, after MSC treatment with differ-
ent volumes of resting or pre-activated lymphocyte CM.
The assay was carried out under the same experimen-
tal conditions as those adopted for the xCELLigence
protocol: 400 MSCs/well were seeded in a 96-well plate
in 200 μL of complete medium; cells were allowed to
proliferate and were treated, after about 72 hours, with
lymphocyte CM at varying dilutions. Control wells were
filled with medium alone to provide the blanks for
absorbance readings and untreated control cells were
included in the assay. To best match the results of
xCELLigence kinetics, the MTT assay was repeated at
different time points, 24, 48 and 72 hours after the
addition of CM; at these time points, 20 μl MTT
(5 mg/ml in PBS) were added to each well, including
controls, and the culture plate returned to the cell
culture incubator for four hours (37°C, 5% CO2). Once in-
cubation ended, the medium was carefully removed and
100 μl DMSO were added to dissolve the intracellular
punctuate purple precipitate that is proportional to the
number of viable living cells. The absorbance was read at
590 nm with a reference filter of 620 nm.
The extent of MTT conversion in treated cells was
expressed as a percentage of the viability of the control
cells. Each experiment was reproduced three times in
duplicate.
Statistical analysis
Analyses were performed using GraphPad Prism v5c
software. Data were evaluated by one-way analysis of
variance (ANOVA) and by Student’s t test.The study was approved by the Institution Research
Board and by the Independent Committee for Bioethics
of the Institute Burlo Garofolo, with reference number
32/11.
Results
Unstimulated PBMCs had little, if any, effect on the
MSC CI. Only at the highest PBMC:MSC ratio (24:1),
could a relevant inhibition of MSC growth be observed,
as evidenced by a halving of the CI (from a CI of 0.656
to 0.327) (Figure 1A and C).
On the contrary, pre-stimulated PBMCs induced a
strong decrease in MSC CI at all ratios, leading in all
cases to a complete inhibition of proliferation (CI from
1.11 to 0.054 for 1:3 ratio and 0 for higher ratios). The
decrease in MSC CI started in less than an hour after
the addition of activated lymphocytes and was faster
at higher PBMC:MSC ratios. Lower ratios of PBMCs
seemed to exert a delayed effect, as a complete inhibi-
tion of MSC growth could be reached in two to three
days, suggesting that they can continue proliferating
and secreting cytokines during the incubation with
MSCs (Figure 1B and C).
The inhibitory capacity of PBMCs on MSCs is retained
after depletion of NK cells (Figure 2). This result is in
agreement with the observation that MSCs were not
able to induce NK activation compared to a conven-
tional tumor cell line, as demonstrated by a CD107a
expression similar to the negative control (Figure 3).
Furthermore, single lymphocyte subsets (CD4+ or CD8+)
maintained a strong inhibitory capacity on MSCs, which
was evident at a 24:1 ratio. However, the effect of CD4+
lymphocytes seemed to be more rapid if compared to
CD8+ cells (data not shown).
A subsequent set of experiments was carried out to
analyze the role of lymphocyte-derived soluble media-
tors on MSC growth. The addition of CM from both
PHA-activated lymphocytes and antiCD3/CD28-acti-
vated lymphocytes inhibited the growth of MSCs in a
dose-dependent manner (Figure 4B and C for PHA-
activated lymphocytes; Additional file 1: Figure A1 for
CD3/CD28-activated lymphocytes). Compared to lympho-
cytes, CM induced a slower decrease in MSC CI. More-
over, only the highest concentration of CM produced a
long lasting inhibition of growth, while a resumption of
cell growth occurred during the last day of incubation in
the presence of lower concentrations of CM.
Cytokine concentration was assessed in PHA-activated
lymphocyte CM, showing high levels of macrophage in-
flammatory protein-1β (MIP-1β), interferon-inducible
protein-10 (IP-10), TNF-α, IFN-γ and IL-2 (Figure 5).
As we have previously shown, licensed MSCs are par-
tially resistant to the action of pre-activated lympho-
cytes, probably because they are able to block lymphocyte
Figure 1 Impedance profiles and mean CI values of MSCs in co-culture with PBMCs. Unstimulated (NS) PBMCs (A) and PHA-stimulated
PBMCs (B) were added to MSCs (400/well) after about 72 hours of culture at four different ratios. The experiment was conducted in triplicate.
(C) The mean CI values, obtained in the four independent experiments, treating MSCs with resting or pre-activated PBMCs. Results were analyzed
and expressed as percentage of the untreated MSCs and presented as mean values ± standard deviations. Statistical analysis was performed using
one-way ANOVA (*P <0.05; **P <0.01; ***P <0.001). ANOVA, analysis of variance; CI, cell index; MSCs, mesenchymal stem cells; PBMCs, peripheral
blood mononuclear cells.
Figure 2 Impedance profiles of MSCs in co-culture with NK-depleted PBMCs. Unstimulated (NS) NK-depleted PBMCs (A) and PHA-stimulated
NK-depleted PBMCs (B) were added to MSCs (400/well), after about 72 hours of culture, at four different ratios. The experiment was conducted in
triplicate. MSCs, mesenchymal stem cells; NK, natural killer; PBMCs, peripheral blood mononuclear cells; PHA, phytohemagglutinin.
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Figure 3 NK degranulation assay. Surface expression of CD107a in resting (A) or pre-activated (B) PBMCs. Three culture conditions were
analyzed: PBMCs alone (negative control), PBMCs with the addition of K562 (positive control) and PBMCs with MSCs. For this flow cytometry assay,
CD3- CD56+ NK cells were gated. MSCs, mesenchymal stem cells; NK, natural killer, PBMCs, peripheral blood mononuclear cells.
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target of lymphocytes [17]. In contrast, pre-exposure to
IFN-γ failed to protect MSCs from the action of CM (see
Additional file 1: Figure A2 and A3).
The diminution of MSC CI after the addition of lym-
phocyte CM was paralleled by a diminution in the number
of viable cells as assessed by the MTT assay; in particular,
the experiment revealed that CM of pre-activated lympho-
cytes led to a progressive dose-dependent reduction in
MSC viability, that was statistically significant only at the
higher dose of CM (50 μl and 100 μl), 48 hours and 72
hours post-stimulation (Figure 6).
Discussion
Although the immunosuppressive potential of MSCs has
been consistently demonstrated in vitro, the use of these
cells in the clinical setting of immune disorders has
remained controversial. Few controlled trials have been
conducted which showed a highly variable efficacy in dif-
ferent patients [8-10]. The cause of such variability
seems not to be attributable to the characteristics ofMSCs themselves or to HLA matching between donor
and recipient, thus suggesting that the immune activa-
tion profiles of each single patient could influence the
action of MSCs. Based on these observations, we argued
that in vitro studies of the immunosuppressive action of
MSCs should be carried out by using pre-stimulated
lymphocytes, that is, lymphocytes that are already acti-
vated when MSCs are added in co-culture. In fact, this
condition may better reflect the state of immune acti-
vation found in clinical situations, where the therapeu-
tic use of MSCs is proposed [17]. We have previously
shown that MSCs are not able to kill pre-stimulated
lymphocytes unless they are pre-treated with IFN-γ (17).
Here, we analyzed the effect of activated lymphocytes on
MSCs by using a new method based on the measure of
electric impedance by means of xCELLigence instru-
mentation, allowing us to calculate a CI that reflects
both growth and viability of adherent MSCs. Although
plate impedance changes are only indirect measures of
cell growth and death, other researchers have shown a
very good correlation of impedance data with those
Figure 4 Impedance profiles and mean CI values of MSCs treated with lymphocyte conditioned medium (CM). MSCs were stimulated
with CM from unstimulated lymphocytes (A) and PHA-stimulated lymphocytes (B). The CM was added to MSCs (400/well) at four different
dilutions after about 72 hours of culture. The experiment was conducted in triplicate. (C) The mean CI values, obtained in the four independent
experiments, treating MSCs with CM from resting or pre-activated PBMCs. Results were analyzed and expressed as percentage of the untreated
MSCs and presented as mean values ± standard deviations. Statistical analysis was performed using one-way ANOVA (*P <0.05; **P <0.01). ANOVA,
analysis of variance; CI, cell index; MSCs, mesenchymal stem cells; PBMCs, peripheral blood mononuclear cells; PHA, phytohemagglutinin.
Figure 5 Measure of different cytokines in the conditioned medium of activated-lymphocytes. Values are expressed in pg/ml.
Non-stimulated lymphocytes: grey bars; lymphocytes stimulated for 24 hours with 1 ug/ml PHA: black bars. The cytokine quantification was
conducted in duplicate. PHA, phytohemagglutinin.
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Figure 6 MTT cell viability assay. Cell viability was assessed after
MSC treatment with the indicated dose of lymphocyte CM. (A) CM
from unstimulated PBMCs; (B) CM from PHA-stimulated PBMCs.
Results were analyzed and expressed as percentage of the control
(untreated MSCs) and presented as mean values ± standard deviations
of the three independent experiments performed in duplicate.
Statistical analysis was performed using Student’s t test (*P <0.05;
**P <0.01). CM, conditioned medium; MSCs, mesenchymal stem
cells; MTT, (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide; PBMCs, peripheral blood mononuclear cells; PHA,
phytohemagglutinin.
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which is based on the cellular protein content [20]. Also,
in our experience, the impedance changes were paral-
leled by similar changes in the MTT assay, confirming
that in our setting electric impedance correlates well
with the number of living cells in the well.
We showed that pre-activated lymphocytes are able to
inhibit the growth of bone marrow-derived MSCs. It
should be noted that non-stimulated lymphocytes did
not significantly affect the growth of MSCs. In contrast,
pre-stimulated lymphocytes induced a complete inhib-
ition of MSC growth, even at the lowest lymphocyte:
MSC ratios. Moreover, the impedance-based method al-
lowed us to track the kinetics of MSC growth; while
higher numbers of lymphocytes produced a dramatic
and rapid effect on the growth of MSCs, lower numbers
had a slower but progressive effect, which led at the end
to the same level of inhibition of MSC growth. This phe-
nomenon probably indicates that stimulated lymphocytescontinue their activation and proliferation regardless of
MSC presence.
Since it has been shown that MSCs can be recognized
and killed by activated NK [15], we hypothesized that
the effect of activated lymphocytes on MSCs could be
mostly due to the presence of activated NK cells. In fact,
we showed that MSCs are not able to trigger NK de-
granulation compared to a conventional tumor cell line.
Moreover, an inhibitory effect on MSCs was maintained
by NK-depleted lymphocytes and similar results were
obtained as well with purified CD4+ or CD8+ subsets.
Yet, resting lymphocytes had little effect, thus indicating
that activation was necessary to induce maximal inhib-
ition of MSC growth. To evaluate whether the inhibitory
effect is due to direct contact between MSCs and lym-
phocytes or to soluble mediators, CM from activated
PBMCs was added to MSCs at different dilutions. Indeed,
CM inhibited MSC growth in a dose-dependent manner,
suggesting that inflammatory cytokines or other mediators
released from activated lymphocytes may have a noxious
effect on MSCs. Notably, only higher concentrations of
CM were able to completely block MSC growth, while
only a transient effect was obtained with a progressive
dilution of CM. Although the growth of IFN-γ-treated
MSCs was only partially affected by pre-activated lympho-
cytes, it was still inhibited by the addition of CM at certain
concentrations. In other words, it is reasonable to state
that interferon treatment is effective in potentiating the
immunosuppressive action of MSCs, giving them the
chance to block the production of lymphocytic media-
tors that, conversely, can affect the growth of MSCs.
It is noteworthy that a noxious effect of inflammatory
cytokines on MSCs has recently been independently
demonstrated by different authors. Freytes and collabo-
rators demonstrated that M1 macrophages, producing
IL-1β, IL-6, TNF-α and IFN-γ, inhibited the growth of
MSC in vitro under certain conditions [20]. Further-
more, Liu and collaborators showed that TNF-α and
IFN-γ derived from activated lymphocytes are able to
block MSC-based bone regeneration [21].
In our setting, TNF-α showed only a limited noxious
effect on MSCs when used at supraphysiological concen-
trations and, thus, it is not likely that it is the main sub-
stance responsible for the inhibitory effect of CM. Other
biologically active compounds, common to different im-
mune cells, may, of course, play a role. Among these
molecules, we could consider nucleotides, such as ATP
and ADP, or tryptophan metabolites, known for their
immune-regulatory properties. Actually, tryptophan me-
tabolites have been implicated in the immunosuppres-
sive mechanisms of MSCs and, therefore, it is unlikely
that they can also affect the viability of MSCs. We, thus,
chose to test the action of ATP in our model. We demon-
strated that the addition of ATP (to a final concentration
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lar to those obtained with CM derived from pre-activated
lymphocytes. This novel finding opened the way to other
experimental analysis to be performed to clarify the role
of nucleotides on MSCs.
The fact that soluble mediators from activated lym-
phocytes can affect the growth of MSCs raises concern
about the use of MSC-based therapies in conditions cha-
racterized by ongoing immune activation. Based on these
results, we can assume that MSCs may survive briefly and
exert limited effects when infused in patients with strong
immune activation. In addition, it could be reasonable to
hypothesize that MSCs may last longer when infused as a
prophylactic treatment before the occurrence of severe
immune activation. In fact, MSCs can survive longer in
mice, when infused just after hematopoietic stem cell
transplantation (HSCT) [22]. However, several reports
suggest a role for stimulated lymphocytes in activating
the immunosuppressive properties of MSCs [23-25]. Thus,
it seems reasonable to hypothesize that the efficacy of
MSC as an immunosuppressant in vivo depends upon sev-
eral factors including: the activation state of lymphocytes,
the concentration of inflammatory cytokines in the micro-
environment; the ratio between MSCs and lymphocytes;
and the licensing of MSCs [26]. As a consequence, the
outcome of the struggle between activated lymphocytes
and MSCs in vivo cannot be easily predicted by preclinical
studies in vitro or in animal models.
Further studies should investigate how different lym-
phocyte mediators can affect MSC growth.
In addition, in vivo studies are needed to track the ef-
fect of the immune activation status on MSC survival.
Conclusions
In conclusion, strategies aimed at activating MSCs and
neutralizing specific mediators released by activated lym-
phocytes can offer new perspectives for immunomodula-
tory cell therapies. However, further studies are needed
to understand the real impact of lymphocyte-derived
mediators on the survival of MSCs infused in vivo.Additional file
Additional file 1: Figure A1. Impedance profiles of MSCs (400 cells/well)
treated with resting or CD3/28-activated PBMC CM. MSCs were stimulated
with CM from unstimulated lymphocytes (A) and from lymphocytes
stimulated with anti CD3/28 beads (B). The CM was added to MSCs
(400/well) at three different dilutions after about 72 hours of culture. The
experiment was conducted in triplicate. Figure A2. Impedance profile of
licensed MSCs in co-culture with PBMCs. Resting (A) or PHA-pre-activated
(B) PBMCs were added at four different ratios to MSCs (400/well) pre-treated
with IFN-γ. The experiment was conducted in triplicate. Figure A3.
Impedance profile of licensed MSCs treated with PBMC CM resting
(A) or pre-activated (B) lymphocyte CM was added at four different
dilutions to MSCs (400/well) pre-treated with IFN-γ. The experiment
was conducted in triplicate.Abbreviations
CI: cell index; CM: conditioned medium; DMSO: dimethyl sulfoxide;
GvHD: graft versus host disease; HLA-I: class I human leukocyte antigen;
HSCT: hematopoietic stem cell transplantation; IFN-γ: interferon-γ; IL:
interleuken; MSC: mesenchymal stromal cell; MTT: 3-(4,5-dimethylthiazol-2-yl)-
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